HK1133583A1 - Albumin-free factor viii formulations - Google Patents

Albumin-free factor viii formulations

Info

Publication number
HK1133583A1
HK1133583A1 HK10100752.6A HK10100752A HK1133583A1 HK 1133583 A1 HK1133583 A1 HK 1133583A1 HK 10100752 A HK10100752 A HK 10100752A HK 1133583 A1 HK1133583 A1 HK 1133583A1
Authority
HK
Hong Kong
Prior art keywords
factor viii
group
albumin
agent selected
raffinose
Prior art date
Application number
HK10100752.6A
Other languages
Unknown language ( )
English (en)
Inventor
Marc Besman
Erik Bjornson
Feroz Jameel
Ramesh Kashi
Michael Pikal
Serguei Tchessalov
John Carpenter
Original Assignee
Univ Connecticut
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26944588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1133583(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Connecticut, Baxter Int filed Critical Univ Connecticut
Publication of HK1133583A1 publication Critical patent/HK1133583A1/

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK10100752.6A 1999-02-22 2007-12-07 Albumin-free factor viii formulations HK1133583A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25527999A 1999-02-22 1999-02-22
US45275299A 1999-12-01 1999-12-01
HK07113386.8A HK1106705A1 (en) 1999-02-22 2007-12-07 Novel albumin-free factor viii formulations

Publications (1)

Publication Number Publication Date
HK1133583A1 true HK1133583A1 (en) 2010-04-01

Family

ID=26944588

Family Applications (4)

Application Number Title Priority Date Filing Date
HK07113386.8A HK1106705A1 (en) 1999-02-22 2007-12-07 Novel albumin-free factor viii formulations
HK10106491.9A HK1139862A1 (en) 1999-02-22 2007-12-07 Albumin-free factor viii formulations viii
HK10100752.6A HK1133583A1 (en) 1999-02-22 2007-12-07 Albumin-free factor viii formulations
HK16101857.2A HK1213801A1 (zh) 1999-02-22 2016-02-18 無白蛋白的因子 製劑

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK07113386.8A HK1106705A1 (en) 1999-02-22 2007-12-07 Novel albumin-free factor viii formulations
HK10106491.9A HK1139862A1 (en) 1999-02-22 2007-12-07 Albumin-free factor viii formulations viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16101857.2A HK1213801A1 (zh) 1999-02-22 2016-02-18 無白蛋白的因子 製劑

Country Status (19)

Country Link
US (8) US6586573B1 (da)
EP (5) EP1154796B1 (da)
JP (9) JP5149470B2 (da)
CN (3) CN101683522B (da)
AT (1) ATE365052T1 (da)
AU (1) AU777972B2 (da)
BR (1) BR0008405B1 (da)
CA (4) CA2634674A1 (da)
CY (2) CY1108030T1 (da)
CZ (3) CZ307715B6 (da)
DE (1) DE60035260T2 (da)
DK (4) DK1154796T3 (da)
ES (4) ES2541470T3 (da)
HK (4) HK1106705A1 (da)
MX (1) MXPA01008515A (da)
PL (4) PL198123B1 (da)
PT (4) PT2130554E (da)
RU (1) RU2244556C2 (da)
WO (1) WO2000048635A1 (da)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US6214054B1 (en) 1998-09-21 2001-04-10 Edwards Lifesciences Corporation Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby
JP5149470B2 (ja) * 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
US6830917B2 (en) * 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
EP1458408B1 (en) * 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US6878168B2 (en) 2002-01-03 2005-04-12 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN101912601B (zh) * 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP1605968A2 (en) * 2003-03-18 2005-12-21 Novo Nordisk Health Care AG Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004103398A1 (en) * 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
MXPA06001283A (es) * 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
KR20120104619A (ko) * 2003-08-14 2012-09-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
EP1670507A4 (en) * 2003-09-12 2007-10-17 Antigenics Inc VACCINE FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY HERPES SIMPLEX VIRUS
EP2311437A1 (en) * 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
AU2005225000A1 (en) * 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
ES2357132T3 (es) * 2004-03-19 2011-04-19 Baxter International Inc. Factor ixa para el tratamiento de trastornos hemorrágicos.
US7319032B2 (en) * 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
PT1835938E (pt) 2004-12-27 2013-11-06 Baxter Int Conjugados de polímero-factor de von willebrand
FR2881139A1 (fr) * 2005-01-26 2006-07-28 Agronomique Inst Nat Rech Composition pour la lyophilisation de proteines
WO2007014073A2 (en) * 2005-07-22 2007-02-01 Amgen Inc. Concentrated protein lyophilates, methods, and uses
KR20110128957A (ko) 2005-11-01 2011-11-30 와이어쓰 엘엘씨 약물 재구성 또는 희석을 위한 염화나트륨 용액
DE602006017421D1 (de) * 2005-11-09 2010-11-18 Ajinomoto Kk Screening-verfahren für kokumi-vermittelnde agentien
WO2007055388A2 (en) 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Calcium receptor activator
US8420144B2 (en) * 2005-11-09 2013-04-16 Ajinomoto Co., Inc. Kokumi-imparting agent, method of using, and compositions containing same
WO2007062040A1 (en) * 2005-11-22 2007-05-31 Wyeth Immunoglobulin fusion protein formulations
WO2007074133A2 (en) 2005-12-28 2007-07-05 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
WO2007139553A1 (en) * 2006-05-31 2007-12-06 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
CA2666485C (en) 2006-10-27 2015-10-06 Edwards Lifesciences Corporation Biological tissue for surgical implantation
EP2535058A3 (en) * 2006-11-07 2013-04-10 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
FR2913020B1 (fr) 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
ES2365832T3 (es) * 2007-03-05 2011-10-11 Cadila Healthcare Limited Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
AU2013204652B2 (en) * 2007-04-26 2015-06-18 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
RU2469739C2 (ru) 2007-04-26 2012-12-20 БАЙЕР ХЕЛСКЕА ЛЛСи Стабилизация жидких растворов рекомбинантного белка для хранения в замороженном состоянии
MY151068A (en) * 2007-05-08 2014-03-31 Ajinomoto Kk Low- fat food
US9101691B2 (en) 2007-06-11 2015-08-11 Edwards Lifesciences Corporation Methods for pre-stressing and capping bioprosthetic tissue
ES2744384T3 (es) * 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
CN101376022B (zh) * 2007-08-31 2011-11-30 上海医药工业研究院 含聚乙二醇降纤酶的药物组合物
US8357387B2 (en) 2007-12-21 2013-01-22 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
US20100316625A1 (en) * 2007-12-21 2010-12-16 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
JP5727790B2 (ja) 2007-12-27 2015-06-03 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 細胞培養プロセス
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
US9884019B2 (en) * 2008-08-05 2018-02-06 Wyeth Llc Lyophilization above collapse
KR101921698B1 (ko) 2008-08-21 2018-11-26 옥타파마 아게 재조합에 의해 제조된 인간 인자 ⅷ 및 ⅸ
MX2011002159A (es) * 2008-08-27 2011-03-29 Schering Corp Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria.
PT2337580E (pt) * 2008-09-03 2012-05-28 Octapharma Ag Composições estabilizadas para o factor viii produzido de forma recombinante
CA2734275A1 (en) * 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
AU2009309623B9 (en) * 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CA2742328C (en) 2008-11-07 2019-02-26 Baxter International Inc. Factor viii formulations
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
WO2011017055A2 (en) 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
ES2590679T3 (es) 2009-07-27 2016-11-23 Lipoxen Technologies Limited Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
KR20210054598A (ko) 2009-09-21 2021-05-13 다케다 야쿠힌 고교 가부시키가이샤 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
JP2013510158A (ja) 2009-11-03 2013-03-21 グリフオルス・セラピユーテイクス・インコーポレーテツド α‐１プロテイナーゼインヒビターのための組成物、方法およびキット
BR112012012460B1 (pt) 2009-11-24 2020-06-23 Grifols Therapeutics Inc. Método de liofilização de uma composição
MX2012008453A (es) * 2010-01-19 2012-11-21 Hanmi Science Co Ltd Formulaciones liquiddas para un conjugado de eritropoientina de accion prolongada.
BR112012023769B1 (pt) 2010-03-23 2020-11-10 Edwards Lifesciences Corporation método para preparar material de membrana de tecido bioprotético
US8906601B2 (en) 2010-06-17 2014-12-09 Edwardss Lifesciences Corporation Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
AU2011301803A1 (en) * 2010-09-17 2013-03-21 Baxalta GmbH Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral pH
ES2639617T3 (es) * 2010-10-12 2017-10-27 Merz Pharma Gmbh & Co. Kgaa Formulación adecuada para estabilizar proteínas, que carece de excipientes de mamíferos
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
MY165089A (en) 2010-11-05 2018-02-28 Baxalta Inc A new variant of antihemophilic factor viii having increased specific activity
US9351829B2 (en) 2010-11-17 2016-05-31 Edwards Lifesciences Corporation Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability
EP2651433A1 (en) * 2010-12-16 2013-10-23 Novo Nordisk A/S Aqueous factor viii solution
MX345608B (es) 2010-12-22 2017-02-07 Baxalta Inc Materiales y metodos para conjugar un derivado de acido graso soluble en agua a una proteina.
BRPI1105317A2 (pt) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
KR102031020B1 (ko) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
CN103703141B (zh) 2011-04-08 2016-08-17 伯乐实验室公司 具有降低的非特异性活性的pcr反应混合物
US8697410B2 (en) 2011-04-08 2014-04-15 Bio-Rad Laboratories, Inc. SSO7-polymerase conjugates with decreased non-specific activity
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US10238771B2 (en) 2012-11-08 2019-03-26 Edwards Lifesciences Corporation Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system
CN105209487A (zh) * 2013-03-15 2015-12-30 拜耳医药保健有限公司 重组因子viii制剂
EA201890671A1 (ru) * 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
KR102058864B1 (ko) * 2013-12-16 2019-12-24 주식회사 티움바이오 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
AU2015240354A1 (en) 2014-04-01 2016-11-17 Advantech Bioscience Farmaceutica Ltda. Stabilization of Factor VIII without calcium as an excipient
WO2015149143A2 (en) * 2014-04-01 2015-10-08 Advantech Bioscience Farmacêutica Ltda. Stable factor viii formulations with low sugar-glycine
MX2017000862A (es) * 2014-08-04 2017-05-01 Csl Ltd Formulacion de factor viii.
CN107073082B (zh) * 2014-08-20 2021-04-30 博尔托拉制药公司 Xa因子解毒剂的冻干制剂
SG11201702757YA (en) * 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016169453A1 (zh) 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 神经生长因子组合物及注射粉剂
CN107660149B (zh) 2015-04-21 2021-04-27 舒泰神（北京）生物制药股份有限公司 一种神经生长因子组合物及注射粉剂
EP3319930A4 (en) * 2015-07-07 2019-04-10 NanoBio Corporation METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS
GB2556002B (en) 2015-07-07 2020-12-16 Bluewillow Biologics Inc Methods and compositions for nanoemulsion vaccine formulations
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
EP3167877A1 (en) * 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Method for the production of freeze-dried pellets comprising factor viii
ES2884119T3 (es) * 2016-02-24 2021-12-10 Alexion Pharma Inc Fórmulas liofilizadas para antídoto contra el factor Xa
SI3463308T1 (sl) * 2016-06-01 2022-04-29 Servier IP UK Limited Formulacije polialkilenoksidne asparaginaze in postopki za pripravo in uporabo le-teh
CN110381962B (zh) * 2016-12-21 2023-10-13 孙崇谨 用于血浆蛋白的活性保存的新颖方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JP6630315B2 (ja) 2017-06-27 2020-01-15 矢崎総業株式会社 ノイズ低減ユニット
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN113382714A (zh) * 2019-01-06 2021-09-10 恩多全球美学有限公司 胶原酶制剂及其制备方法
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
CN110772487B (zh) * 2019-12-09 2021-09-21 湖南科伦制药有限公司 一种二乙酰氨乙酸乙二胺的冻干方法
CN112121009B (zh) * 2020-09-24 2022-12-02 科兴生物制药股份有限公司 一种聚乙二醇修饰重组人粒细胞刺激因子新制剂
TW202227133A (zh) 2020-09-24 2022-07-16 美商默沙東藥廠 計畫性死亡受體1(pd-1)抗體及玻尿酸酶變異體及其片段之穩定調配物及其使用方法
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
WO2022217041A1 (en) * 2021-04-09 2022-10-13 Hyalo Technologies, LLC Method of sterilization of biologics
CA3228445A1 (en) * 2021-08-11 2023-02-16 Salvador Grancha Gamon Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained
CN114015758B (zh) * 2021-10-15 2022-06-24 无锡百泰克生物技术有限公司 一种冻干保护剂、荧光pcr检测试剂盒及冻干工艺

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB941019A (en) 1961-04-27 1963-11-06 Crookes Lab Ltd Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
US3389314A (en) 1962-05-07 1968-06-18 Penn Controls Proportional silicon controlled rectifier driven system for a heat motor
US3681126A (en) 1969-11-25 1972-08-01 Monsanto Co Flame retardant article containing tris-(3 - halo - 2-hydroxypropyl)-hydroxymethylphosphonium chloride
US3770631A (en) 1971-06-29 1973-11-06 Baxter Laboratories Inc Clarification of blood serum and plasma
US3839314A (en) 1971-06-29 1974-10-01 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US4073886A (en) 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3980432A (en) 1973-04-02 1976-09-14 Behringwerke Aktiengesellschaft Partial thromboplastin, its use as diagnostic agent and process for preparing it
US3893990A (en) 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene
US3893991A (en) 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US4189425A (en) 1975-04-11 1980-02-19 Edward Shanbrom, Inc. Method of preserving blood plasma I
US4086218A (en) 1975-04-11 1978-04-25 Edward Shanbrom, Inc. Method of preserving blood plasma II
US4069216A (en) 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4089944A (en) 1975-12-22 1978-05-16 Baxter Travenol Laboratories, Inc. Rapidly solubilized AHF composition and process for preparing same
US4027013A (en) 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
SU663404A1 (ru) 1976-12-30 1979-05-25 Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Им. М.В.Ломоносова Способ получени фибрин-мономера
US4137223A (en) 1977-05-16 1979-01-30 Edward Shanbrom, Inc. Method of preserving blood plasma II
SE443293B (sv) 1978-01-25 1986-02-24 Blombaeck E G B Blodfraktionsframstellning
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
FR2460305A2 (fr) 1979-06-29 1981-01-23 Merieux Inst Procede de preparation d'un concentre de facteur viii
US4386068A (en) 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
US4623717A (en) 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
DE3176491D1 (en) 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4440679A (en) 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
JPS56127308A (en) 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical
JPS56135418A (en) 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
AT369263B (de) 1980-08-27 1982-12-27 Immuno Ag Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
DE3033932C2 (de) 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten
JPS5770814A (en) 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4382083A (en) 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4479938A (en) 1981-06-25 1984-10-30 Baxter Travenol Laboratories, Inc. Therapeutic composition containing factor VIIa
JPS5874617A (ja) 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
US4456590B2 (en) 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4591505A (en) 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
US4481189A (en) 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4495175A (en) 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
DE3230849A1 (de) 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
DE3237512A1 (de) 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
GB2129685B (en) 1982-11-11 1985-11-13 Nat Biolog Standards Board Anti-haemophilic compositions
JPS59134730A (ja) 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
WO1984003628A1 (en) 1983-05-09 1984-09-27 Nordisk Insulinlab A concentrate of the antihemophilic factor viii and a process for producing it
IE80858B1 (en) 1983-03-31 1999-04-21 Scripps Research Inst New factor viii coagulant polypeptides
US4727027A (en) 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4748120A (en) 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
AT379510B (de) 1983-05-20 1986-01-27 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
DE3318521A1 (de) 1983-05-20 1984-11-22 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
DE3336631A1 (de) 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
JPS6122022A (ja) 1983-12-28 1986-01-30 Green Cross Corp:The 血漿蛋白の加熱処理方法
EP0150735B2 (en) 1984-01-12 2004-01-07 Chiron Corporation Protein composition exhibiting coagulation activity and method for the preparation thereof
WO1987000196A1 (en) 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4831012A (en) 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
JPS60199829A (ja) 1984-03-24 1985-10-09 Nippon Sekijiyuujishiya 高純度抗血友病グロブリンの製造方法
US5043428A (en) 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
US4543210A (en) 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
US4613501A (en) 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
JPS61271222A (ja) * 1985-05-24 1986-12-01 Dainippon Pharmaceut Co Ltd ヒトインターロイキン１ポリペプチド及びその製造法
US4847362A (en) 1985-02-01 1989-07-11 New York University Method for purifying antihemophilic factor
US4952675A (en) 1985-02-01 1990-08-28 New York University Method for purifying antihemophilic factor
US4743680A (en) 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
US4758657A (en) 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
EP0212040B1 (de) 1985-08-05 1990-05-23 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren
AU6487286A (en) 1985-11-08 1987-05-14 Baxter Travenol Laboratories Inc. Antihemophilic factor by cold precipitation
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
JPS62195331A (ja) 1986-02-24 1987-08-28 Nippon Sekijiyuujishiya 血液凝固第８因子製剤の製法
AT390374B (de) 1986-03-18 1990-04-25 Schwab & Co Gmbh Verfahren zum pasteurisieren von plasmaprotein und plasmaproteinfraktionen
DE3609431A1 (de) 1986-03-20 1987-09-24 Biotest Pharma Gmbh Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates
US4841023A (en) 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
AT391808B (de) 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
GB8628104D0 (en) 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
ES2006632A6 (es) 1987-04-21 1989-05-01 Green Cross Corp Procedimiento de tratamiento termico de fibrinogeno.
IL86417A (en) 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
US4876241A (en) 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US4795806A (en) 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DE3730533A1 (de) 1987-09-11 1989-03-30 Biotest Pharma Gmbh Verfahren zur sterilisation von plasma oder plasmafraktionen
KR890004724A (ko) * 1987-09-17 1989-05-09 히사시 미하라 신규 프로테아제 제제(製劑)
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5177191A (en) 1987-12-21 1993-01-05 Miles, Inc. Gel filtration of factor VIII
DK18288D0 (da) 1988-01-15 1988-01-15 Nordisk Gentofte Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
US4981951A (en) 1988-04-14 1991-01-01 Miles Inc. Lectin affinity chromatography of factor VIII
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
US5047249A (en) 1988-07-22 1991-09-10 John Morris Co., Inc. Compositions and methods for treating skin conditions and promoting wound healing
US5051353A (en) 1988-08-09 1991-09-24 The United States Of America As Represented By The Secretary Of The Navy Preservation and restoration of hemoglobin in blood substitutes
JPH02157231A (ja) * 1988-12-07 1990-06-18 Bio Kagaku Kenkyusho:Kk 細胞増殖抑制剤
DE3904354A1 (de) 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2665449B1 (fr) 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
US5760183A (en) 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
CN1047342A (zh) 1989-05-13 1990-11-28 杭州市中心血站 因子viii的生产及其病毒灭活方法
ES2042138T3 (es) 1989-05-24 1993-12-01 Miles Inc. Filtracion en gel del factor viii tratado termicamente.
GB8913183D0 (en) * 1989-06-08 1989-07-26 Central Blood Lab Authority Chemical products
US5138034A (en) 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5062498A (en) 1989-07-18 1991-11-05 Jaromir Tobias Hydrostatic power transfer system with isolating accumulator
EP0410207B1 (en) 1989-07-24 1997-01-22 Bayer Corporation Stabilization of highly purified proteins
DE3926034C3 (de) 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
FR2651437A1 (fr) 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5439882A (en) 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5798238A (en) 1990-04-16 1998-08-25 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer
US5587490A (en) 1990-04-16 1996-12-24 Credit Managers Association Of California Method of inactivation of viral and bacterial blood contaminants
WO1991017194A1 (en) * 1990-05-07 1991-11-14 Exxon Chemical Patents Inc. UNSATURATED α-OLEFIN COPOLYMERS AND METHOD FOR PREPARATION THEREOF
US5378612A (en) 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5712086A (en) 1990-05-15 1998-01-27 New York Blood Center, Inc. Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions
FR2662166A1 (fr) 1990-05-18 1991-11-22 Fondation Nale Transfusion San Procede de preparation de facteur viii de tres haute purete comprenant une etape rapide d'immunoadsorption.
IT1248723B (it) 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
WO1992001229A1 (en) 1990-07-12 1992-01-23 Baxter Diagnostics Inc. FACTOR VIII:Ca CHROMOGENIC ASSAY
CA2051092C (en) 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
SE468480B (sv) 1991-05-24 1993-01-25 Arne Holmgren Modifierat tioredoxin och dess anvaendning
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
US5254350A (en) 1991-07-22 1993-10-19 Helena Laboratories Corporation Method of preparing a thromboplastin extract
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
US5278289A (en) 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
JPH05331071A (ja) * 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
AT399818B (de) 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5399670A (en) 1992-04-30 1995-03-21 Alpha Therapeutic Corporation Solubilization and stabilization of factor VIII complex
US5378601A (en) 1992-07-24 1995-01-03 Montefiore Medical Center Method of preserving platelets with apyrase and an antioxidant
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
IT1256622B (it) 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
JPH08506498A (ja) 1993-02-09 1996-07-16 オクタファルマ・アクチエンゲセルシャフト 非脂質被覆ウイルスの失活方法
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5576291A (en) 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5353835A (en) 1993-09-23 1994-10-11 Ingersoll-Rand Company Air tank drain
IT1268920B1 (it) 1994-03-29 1997-03-13 Syfal Srl Macchina rotativa per la decorazione-smaltatura in particolare dipiastrelle ceramiche.
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5514781A (en) 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
DK0762897T3 (da) 1994-06-02 2003-07-21 Elan Drug Delivery Ltd Fremgangsmåde til forebyggelse af aggregering af proteiner/peptider ved rehydratisering eller optøning
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
DE4431833C1 (de) 1994-09-07 1995-05-18 Blutspendedienst Der Drk Lande Verfahren zur Herstellung eines AHF-Konzentrates
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
WO1996019918A1 (en) * 1994-12-28 1996-07-04 Biotime, Inc. Plasma expanders and blood substitutes
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5679549A (en) 1995-05-04 1997-10-21 Bayer Corporation Production of recombinant factor VIII in the presence of liposome-like substances of mixed composition
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
KR0167677B1 (ko) * 1995-08-31 1999-02-01 김광호 다중 비트 테스트를 위한 패턴 발생기를 가지는 메모리 테스트 시스템
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
ES2099678B1 (es) 1995-11-03 1998-02-16 Grifols Grupo Sa Procedimiento para la inactivacion de virus en proteinas.
JP2000500137A (ja) 1995-11-06 2000-01-11 ニューヨーク・ブラッド・センター・インコーポレイテッド フタロシアニン及び赤色光を用いた赤血球細胞のウイルス不活性化処理
US5659017A (en) 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US5925738A (en) 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP5149470B2 (ja) * 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
NZ516400A (en) 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
PT2337580E (pt) 2008-09-03 2012-05-28 Octapharma Ag Composições estabilizadas para o factor viii produzido de forma recombinante

Also Published As

Publication number Publication date
JP2018172413A (ja) 2018-11-08
US20120083446A1 (en) 2012-04-05
PL203893B1 (pl) 2009-11-30
MXPA01008515A (es) 2003-06-06
CZ307322B6 (cs) 2018-06-06
PL198123B1 (pl) 2008-05-30
AU2884300A (en) 2000-09-04
HK1139862A1 (en) 2010-09-30
JP6253627B2 (ja) 2017-12-27
JP2012072198A (ja) 2012-04-12
US20040116345A1 (en) 2004-06-17
CN101683522A (zh) 2010-03-31
EP1820516A2 (en) 2007-08-22
JP5006832B2 (ja) 2012-08-22
EP2193809A1 (en) 2010-06-09
CA2634663C (en) 2009-08-25
CZ307715B6 (cs) 2019-03-06
US9669076B2 (en) 2017-06-06
JP6155442B2 (ja) 2017-07-05
JP2014024864A (ja) 2014-02-06
BR0008405A (pt) 2002-04-30
CZ20012996A3 (cs) 2002-03-13
AU777972B2 (en) 2004-11-04
JP2008201801A (ja) 2008-09-04
BR0008405B1 (pt) 2014-04-22
WO2000048635A1 (en) 2000-08-24
DK1820516T3 (da) 2013-10-28
JP2003520764A (ja) 2003-07-08
US6586573B1 (en) 2003-07-01
US20170000854A1 (en) 2017-01-05
ES2288843T3 (es) 2008-02-01
US9352027B2 (en) 2016-05-31
EP2130554A1 (en) 2009-12-09
HK1106705A1 (en) 2008-03-20
EP1820516A3 (en) 2009-10-07
CN101683522B (zh) 2013-05-01
RU2244556C2 (ru) 2005-01-20
DE60035260D1 (de) 2007-08-02
US20060205661A1 (en) 2006-09-14
DK1154796T3 (da) 2007-09-24
JP5596064B2 (ja) 2014-09-24
PL204701B1 (pl) 2010-02-26
JP6038003B2 (ja) 2016-12-07
ATE365052T1 (de) 2007-07-15
JP2016040310A (ja) 2016-03-24
CN1399560A (zh) 2003-02-26
DK2193809T3 (da) 2015-05-26
US20080176791A1 (en) 2008-07-24
CA2634664C (en) 2011-08-09
EP1820516B1 (en) 2013-07-24
US8765665B2 (en) 2014-07-01
CA2634664A1 (en) 2000-08-24
US8058226B2 (en) 2011-11-15
EP1154796B1 (en) 2007-06-20
US20130184216A1 (en) 2013-07-18
HK1213801A1 (zh) 2016-07-15
ES2435141T3 (es) 2013-12-18
JP5149470B2 (ja) 2013-02-20
ES2394755T3 (es) 2013-02-05
US7247707B2 (en) 2007-07-24
CA2362927A1 (en) 2000-08-24
US7087723B2 (en) 2006-08-08
JP2015091902A (ja) 2015-05-14
PL203177B1 (pl) 2009-09-30
JP5140539B2 (ja) 2013-02-06
CA2634674A1 (en) 2000-08-24
DE60035260T2 (de) 2007-10-18
CA2634663A1 (en) 2000-08-24
CN100553678C (zh) 2009-10-28
CZ307715A3 (cs) 2002-03-13
PT2193809E (pt) 2015-08-24
CZ300547B6 (cs) 2009-06-10
PT1820516E (pt) 2013-10-31
US8372800B2 (en) 2013-02-12
DK2130554T3 (da) 2012-12-03
PL356453A1 (en) 2004-06-28
EP2130554B1 (en) 2012-09-05
CY1108030T1 (el) 2013-09-04
CN101810854A (zh) 2010-08-25
PT2130554E (pt) 2012-11-19
PT1154796E (pt) 2007-09-28
US20150025010A1 (en) 2015-01-22
CA2362927C (en) 2011-07-12
EP2921180A1 (en) 2015-09-23
JP2017125076A (ja) 2017-07-20
EP2921180B1 (en) 2019-08-14
EP1154796A1 (en) 2001-11-21
JP2009046499A (ja) 2009-03-05
EP2193809B1 (en) 2015-04-08
CY1113969T1 (el) 2016-07-27
ES2541470T3 (es) 2015-07-20

Similar Documents

Publication Publication Date Title
HK1213801A1 (zh) 無白蛋白的因子 製劑
GB9930882D0 (en) GLP-2 formulations
DK0955062T3 (da) Vandig formulering indeholdende humant væksthormon
RU2001125929A (ru) Новые не содержащие альбумин составы фактора viii
CA2315141A1 (en) Pharmaceutical compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof
HUT72325A (en) Stabile, liophylised composition containing proteins and kit applicabe for dosing
TR200200706T2 (tr) Nöropatik ağrı tedavisi için retigabin kullanımı.
PL319603A1 (en) Stable aqueous alpha interferon preparations
ATE270898T1 (de) Stabile igf/igfbp pharmazeutische formulierungen
CA2326222A1 (en) Medicinal compositions
MX9710206A (es) Composicion farmaceutica de amiodarone para administracion parenteral.
CA2226548A1 (en) Lyophilized hepatocyte growth factor preparations
EP1369119A4 (en) IL-12 EXPRESSION REGULATORS
CA2266486A1 (en) Rotavirus vaccine formulations
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
CA2275153A1 (en) Pharmaceutical compositions for freeze drying
AR034749A1 (es) Formulaciones de interferon beta humano
AP9801350A0 (en) Parasitical formulations.
PT925781E (pt) Composicao para despigmentacao
ES2149691A1 (es) 2-4-[4-(4,5-dicloro-2metilimidazol-1-il)butil]-1-piperacinil -5-fluoropirimidina, su preparacion y su utilizacion terapeutica.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170222